# Edgar Filing: IMMTECH PHARMACEUTICALS, INC. - Form S-3MEF

IMMTECH PHARMACEUTICALS, INC.

Form S-3MEF February 07, 2007	
As filed with the Securities and Exchange Comm	nission on February 8, 2007
Registration No. 333	
UNITED STATES SECURITIES AND EXCHA	NGE COMMISSION
Washington, D.C. 20549	
FORM S-3	
REGISTRATION STATEMENT UNDER THE	SECURITIES ACT OF 1933
Immtech Pharmaceuticals, Inc.	
(Exact name of registrant as specified in its charter)	
Delaware (State or other jurisdiction of incorporation or organization)	39-1523370 (I.R.S. Employer Identification Number)
One North End Avenue	
New York, NY 10282	
(212) 791-2911	
(Address, including zip code, and telephone number, in	ncluding area code, of registrant s principal executive offices)
Eric L. Sorkin	
Chief Executive Officer	
Immtech Pharmaceuticals, Inc.	
One North End Avenue	
New York, NY 10282	
(212) 791-2911	
(Name, address, including zip code, and telephone num	iber, including area code, of agent for service)
Copy To:	

# Edgar Filing: IMMTECH PHARMACEUTICALS, INC. - Form S-3MEF

Elizabeth Brower, Esq.				
Paul, Hastings, Janofsky &	Walker LLP			
1055 Washington Boulevar	d			
Stamford, CT 06901				
(203) 961-7400				
Approximate date of comm	nencement of sale of the securities to the	e public:		
As soon as practicable after t	his registration statement becomes effec	tive.		
If the only securities being refollowing box. [ ]	egistered on this form are being offered p	oursuant to dividend	or interest reinvest	ment plans, please check the
	registered on this form are to be offered rities offered only in connection with div			
	r additional securities for an offering pure ct registration statement number of the ea			
	e amendment filed pursuant to Rule 462 umber of the earlier effective registration			Following box and list the Securities
	statement pursuant to General Instruction sion pursuant to Rule 462(e) under the S			
	e amendment to a registration statement es of securities pursuant to Rule 413(b) u			
CALCULATION OF REG	ISTRATION FEE			
Title of Each Class of	Amount	Proposed Maximum	Proposed Maximum	
Securities to be	to be	Offering Price	Aggregate	Amount of
Registered	Registered	Per Share	Offering Price	Registration Fee
Common stock, par value \$.01 per share	200,000 shares	\$6.75	\$1,350,000	\$144.45

#### **EXPLANATORY NOTE**

This registration statement is being filed to register additional shares of common stock of Immtech Pharmaceuticals, Inc. pursuant to Rule 462(b) under the Securities Act of 1933, as amended. A Registration Statement on Form S-3, Commission File No. 333-130970 (the Prior Registration Statement), to which this registration statement relates was declared effective by the Securities and Exchange Commission on February 7, 2006. The contents of the Prior Registration Statement are incorporated herein by reference.

1

#### PART II

#### INFORMATION NOT REQUIRED IN PROSPECTUS

Item 16. Exhibits.

**Exhibit** 

NumberDescription of Document5.1Opinion of Paul, Hastings, Janofsky & Walker LLP23.1Consent of Deloitte & Touche LLP23.2Consent of Paul, Hastings, Janofsky & Walker LLP (included in exhibit 5.1).

II-1

### **SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of New York, State of New York, on the 7th day of February, 2007.

IMMTECH PHARMACEUTICALS, INC.

### Edgar Filing: IMMTECH PHARMACEUTICALS, INC. - Form S-3MEF

By: /s/ Eric L. Sorkin

Name: Eric L. Sorkin

Title: Chairman, President and Chief Executive

Officer

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature	<u>Title</u>	<u>Date</u>
/s/ Eric L. Sorkin Eric L. Sorkin	Chairman, President and Chief Executive Officer	February 7, 2007
/s/ Gary C. Parks Gary C. Parks	Chief Financial Officer	February 7, 2007
/s/ Cecilia Chan Cecilia Chan	Director and Executive Director	February 7, 2007
/s/ Harvey R. Colten Harvey R. Colten, M.D.	Director	February 7, 2007
/s/ Judy Lau Judy Lau	Director	February 7, 2007
/s/ Levi H.K. Lee Levi H.K. Lee, M.D.	Director	February 7, 2007
/s/ Donald F. Sinex Donald F. Sinex	Director	February 7, 2007
/s/ Frederick W. Wackerle Frederick W. Wackerle	Director	February 7, 2007

II-2

#### EXHIBIT INDEX

Exhibit	
Number	Description of Document
5.1	Opinion of Paul, Hastings, Janofsky & Walker LLP
23.1	Consent of Deloitte & Touche LLP
23.2	Consent of Paul, Hastings, Janofsky & Walker LLP (included in exhibit 5.1).